Eli Lilly

Category

Eli Lilly’s BLAZE-1 Selects Aventiv Research in Columbus as Ohioans Investigate Advanced Monoclonal Antibodies Targeting COVID-19

TrialSite recently profiled Columbus, Ohio-based Aventiv Research as the independent trial site organization was selected by Pfizer as a site to participate in the BNT162 COVID-19 vaccine trial program. Now, local media (WSYX/WTTE) reports that the Columbus-based site...

Prominent New Orleans Physician Discusses Participation in Blaze-1 Study of World’s First Antibody Product Targeting COVID-19

Louisiana’s Ochsner Medical Center in Jefferson Parish is actively contributing its medical, scientific and research talents in the ongoing bid to combat the COVID-19 pandemic. Partnering with industry sponsors such as Eli Lilly, one the health provider’s prestigious...

Eli Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients

Eli Lilly and Company announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults...

Duke Clinical Research Institute Collaborates with BI & Eli Lilly to Lead EMPACT-MI Pragmatic Clinical Trial

Duke Clinical Research Institute (DCRI) inked a clinical trials collaborative deal with the world’s largest privately held drug company—Boehringer Ingelheim—and publicly traded Eli Lilly (NYSE:LLY) to launch the EMPACT-MI (EMPAgliflozin for the prevention of Chronic...